Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis

Objective To evaluate the impact on structural lesions observed on MRI in the sacroiliac joints (SIJ) at 12 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving etanercept or placebo in EMBARK (Effect of Etanercept on Symptoms and Objective Inflammation in nr-axSpA, a 104 week study). Methods Patients were randomised to double-blind etanercept 50 mg/week or placebo for 12 weeks. Structural lesions at baseline and 12 weeks were scored by two independent readers using the Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ structural score (SSS) on T1-weighted MRI. Change in SPARCC SSS and correlation with improvement in clinical outcomes was evaluated. Results MRI scans from 185 patients (etanercept, n=88; placebo, n=97) were reviewed. At baseline, there were no significant differences in mean SPARCC SSS between etanercept and placebo. From baseline to 12 weeks, change in mean SPARCC SSS was significantly greater for etanercept than placebo for erosion (–0.57 vs –0.08, respectively, adjusted p value=0.017) and backfill (0.36 vs 0.06, adjusted p value=0.022). A treatment difference was also present for the subgroup of patients with SIJ inflammation on MRI (SPARCC bone marrow oedema ≥2): erosion: –0.81 versus –0.13 for etanercept versus placebo, respectively, p=0.007; backfill: 0.48 versus 0.08, respectively, p=0.032. Decrease in erosion and increase in backfill correlated with improvement in more clinical outcomes for etanercept than placebo. Conclusion Treatment with etanercept was associated with significantly greater reduction in erosions and increase in backfill at 12 weeks compared with placebo, consistent with a very early reparative response to antitumour necrosis factor therapy. The impact on disease progression in spondyloarthritis should be studied further. Trial registration number NCT01258738; Post-results.

[1]  M. Dougados,et al.  Effects of Long‐Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104‐Week Results From a Randomized, Placebo‐Controlled Study , 2017, Arthritis care & research.

[2]  A. Loft,et al.  Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double‐Blind, Placebo‐Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium , 2016, Arthritis & rheumatology.

[3]  R. Landewé,et al.  MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis , 2015, Annals of the rheumatic diseases.

[4]  M. Dougados,et al.  Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study , 2015, Annals of the rheumatic diseases.

[5]  D. M. van der Heijde,et al.  Metric Properties of the SPARCC Score of the Sacroiliac Joints — Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort , 2015, The Journal of Rheumatology.

[6]  W. Maksymowych,et al.  Development and Preliminary Validation of the Spondyloarthritis Research Consortium of Canada Magnetic Resonance Imaging Sacroiliac Joint Structural Score , 2015, The Journal of Rheumatology.

[7]  W. Maksymowych,et al.  Fat Metaplasia and Backfill Are Key Intermediaries in the Development of Sacroiliac Joint Ankylosis in Patients With Ankylosing Spondylitis , 2014, Arthritis & rheumatology.

[8]  M. Dougados,et al.  Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[9]  W. Maksymowych,et al.  Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis , 2014, Arthritis Research & Therapy.

[10]  M. Brown,et al.  Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis , 2014, Arthritis & rheumatology.

[11]  J. Listing,et al.  Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers , 2014, Arthritis Research & Therapy.

[12]  M. Dougados,et al.  Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography , 2013, Annals of the rheumatic diseases.

[13]  R. Landewé,et al.  MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor , 2012, Annals of the rheumatic diseases.

[14]  K. Rufibach,et al.  Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study , 2012, Arthritis Research & Therapy.

[15]  W. Maksymowych,et al.  Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. , 2011, Arthritis and rheumatism.

[16]  J. Listing,et al.  Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48 , 2011, Annals of the rheumatic diseases.

[17]  J. Hodler,et al.  Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of MRI in early spondyloarthritis , 2010 .

[18]  J. Hodler,et al.  Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis , 2010, Arthritis care & research.

[19]  M. Østergaard,et al.  Structural Lesions Detected by Magnetic Resonance Imaging in the Spine of Patients with Spondyloarthritis – Definitions, Assessment System, and Reference Image Set , 2009, The Journal of Rheumatology. Supplement.

[20]  D. M. van der Heijde,et al.  Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group , 2009, Annals of the rheumatic diseases.

[21]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis , 2009, Annals of the rheumatic diseases.

[22]  L. Coates,et al.  Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. , 2008, Arthritis and rheumatism.

[23]  S. van der Linden,et al.  Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain , 2005, Annals of the rheumatic diseases.

[24]  David Salonen,et al.  Spondyloarthritis Research Consortium of Canada Magnetic Resonance Imaging Index For Assessment of Sacroiliac Joint Inflammation in Ankylosing Spondylitis , 2005 .

[25]  David Salonen,et al.  Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. , 2005, Arthritis and rheumatism.

[26]  M. A. van de Laar,et al.  Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. , 1999, The Journal of rheumatology.

[27]  E. L. Persons,et al.  Ankylosing Spondylitis , 1955, GP.